Charles Schwab Investment Management Inc. Boosts Stock Position in ADMA Biologics Inc $ADMA

Key Points

• Charles Schwab Investment Management Inc. increased its stake in ADMA Biologics Inc. by 0.9%, holding approximately 2,462,005 shares valued at $48.8 million.
• Several institutional investors, including New York State Teachers Retirement System and GAMMA Investing LLC, have significantly increased their positions in ADMA Biologics, reflecting growing interest in the biotechnology company.
• ADMA Biologics reported a 13.8% increase in quarterly revenue year-over-year and surpassed earnings expectations with $0.15 EPS, indicating strong financial performance.

Charles Schwab Investment Management Inc. lifted its position in ADMA Biologics Inc (NASDAQ:ADMA - Free Report) by 0.9% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,462,005 shares of the biotechnology company's stock after purchasing an additional 21,711 shares during the quarter. Charles Schwab Investment Management Inc. owned 1.04% of ADMA Biologics worth $48,846,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Dimensional Fund Advisors LP lifted its stake in shares of ADMA Biologics by 16.0% in the 4th quarter. Dimensional Fund Advisors LP now owns 4,668,320 shares of the biotechnology company's stock valued at $80,065,000 after acquiring an additional 643,661 shares during the last quarter. Oberweis Asset Management Inc. lifted its stake in shares of ADMA Biologics by 15.0% in the 4th quarter. Oberweis Asset Management Inc. now owns 3,342,560 shares of the biotechnology company's stock valued at $57,325,000 after acquiring an additional 435,480 shares during the last quarter. Allspring Global Investments Holdings LLC lifted its stake in shares of ADMA Biologics by 7.3% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 3,048,946 shares of the biotechnology company's stock valued at $59,211,000 after acquiring an additional 207,097 shares during the last quarter. Northern Trust Corp lifted its stake in shares of ADMA Biologics by 6.0% in the 4th quarter. Northern Trust Corp now owns 2,575,075 shares of the biotechnology company's stock valued at $44,163,000 after acquiring an additional 145,387 shares during the last quarter. Finally, B Group Inc. bought a new stake in shares of ADMA Biologics in the 4th quarter valued at about $39,231,000. 75.68% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at ADMA Biologics

In other news, Director Steve Elms sold 194,749 shares of the stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $20.24, for a total value of $3,941,719.76. Following the completion of the transaction, the director owned 87,330 shares of the company's stock, valued at approximately $1,767,559.20. This represents a 69.04% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Jerrold B. Grossman sold 10,000 shares of the stock in a transaction that occurred on Monday, June 9th. The stock was sold at an average price of $21.31, for a total value of $213,100.00. Following the completion of the transaction, the director directly owned 478,194 shares of the company's stock, valued at $10,190,314.14. This represents a 2.05% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 456,842 shares of company stock valued at $9,486,200. Corporate insiders own 3.70% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the company. Raymond James Financial boosted their target price on ADMA Biologics from $25.00 to $32.00 and gave the company a "strong-buy" rating in a research note on Thursday, May 8th. Wall Street Zen lowered ADMA Biologics from a "hold" rating to a "sell" rating in a research note on Friday, May 9th. One analyst has rated the stock with a Strong Buy rating and two have issued a Buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Buy" and an average price target of $27.67.

ADMA Biologics Trading Down 2.4%

ADMA traded down $0.42 during midday trading on Wednesday, reaching $17.02. 624,933 shares of the company's stock traded hands, compared to its average volume of 3,133,360. The firm has a fifty day moving average of $18.15 and a two-hundred day moving average of $18.87. The stock has a market capitalization of $4.06 billion, a price-to-earnings ratio of 19.84 and a beta of 0.38. The company has a debt-to-equity ratio of 0.21, a current ratio of 5.33 and a quick ratio of 2.78. ADMA Biologics Inc has a 52 week low of $13.50 and a 52 week high of $25.67.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The biotechnology company reported $0.15 EPS for the quarter, beating analysts' consensus estimates of $0.14 by $0.01. ADMA Biologics had a return on equity of 41.01% and a net margin of 44.06%.The business had revenue of $121.98 million during the quarter, compared to analyst estimates of $121.77 million. During the same quarter in the prior year, the company posted $0.13 EPS. ADMA Biologics's quarterly revenue was up 13.8% compared to the same quarter last year. On average, equities analysts anticipate that ADMA Biologics Inc will post 0.51 earnings per share for the current fiscal year.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.